The earnings call emphasizes significant progress in the development of CD388, demonstrating promising results in early trials and advancing to a phase 2b study. There is optimism around the potential phase 3 study and the commercial opportunity, highlighted by the planned R&D day. However, the company's current non-revenue generating status and challenges with the NAVIGATE study's design and dose-dependent efficacy present notable concerns.

Company Guidance -

Q3 2025

During the earnings call for the first quarter of 2025, Cidara Therapeutics, Inc. focused on the progress of their lead asset, CD388, a novel drug designed to prevent influenza. The company highlighted the completion of dosing for the phase 2b NAVIGATE study, which involved 5,041 subjects randomized into three dose groups (150 mg, 300 mg, or 450 mg) and one placebo group. Top-line data from this study, which was not initially powered for statistical significance, are expected by June 2025. Due to the severity of the February 2025 flu season, Cidara is in discussions with the FDA to potentially amend the study's statistical analysis to evaluate the statistical significance of CD388's efficacy. CD388 has shown promise in preclinical and early-phase clinical trials, demonstrating substantial protective efficacy and a well-tolerated safety profile, with potential broad applications beyond the initial target populations. The company plans to initiate a phase 3 study in the Southern Hemisphere in February 2026, focusing on high-risk and immune-compromised populations.

Introduction of CD388

CD388 aims to revolutionize the prevention of influenza by offering universal activity against all flu strains, not dependent on the host immune system, and combines a novel multivalent presentation of zanamivir with a human antibody fragment to prolong half-life.

Successful Phase 1 and Phase 2a Trials

Phase 1 single ascending dose study showed CD388 to be well tolerated with an extended half-life. Phase 2a human challenge study showed substantial protective efficacy, supporting its advancement to a phase 2b study.

Progress of NAVIGATE Phase 2b Study

NAVIGATE study completed dosing of 5,041 subjects by December, with top-line data expected by June. The study aims to determine dose selection for phase three.

Potential Phase 3 Study

Based on phase 2b results and FDA discussions, a phase 3 study is planned for February in high-risk comorbid and immune-compromised patients, addressing unmet needs.

R&D Day Announcement

An R&D day is planned for May 22 to provide updates on the NAVIGATE trial, regulatory discussions, and phase 3 plans, emphasizing the potential commercial opportunity for CD388.

Cidara Therapeutics (CDTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CDTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	-2.45	―	―	―
Aug 07, 2025	2025 (Q2)	-1.94 / -1.65	-19.99	91.75% (+18.34)	―	―
May 08, 2025	2025 (Q1)	-3.54 / -1.66	-2.28	27.19% (+0.62)	―
Mar 06, 2025	2024 (Q4)	-3.62 / -5.37	-0.8	-571.25% (-4.57)	―	―
Nov 07, 2024	2024 (Q3)	-4.25 / -2.45	-1.8	-36.11% (-0.65)	―	―
Aug 13, 2024	2024 (Q2)	-4.10 / -19.99	-2.8	-613.93% (-17.19)	―	―
May 15, 2024	2024 (Q1)	-2.39 / -2.28	0.6	-480.00% (-2.88)	―	―
Feb 28, 2024	2023 (Q4)	-1.50 / -0.80	-3.8	78.95% (+3.00)	―	―
Nov 02, 2023	2023 (Q3)	-3.00 / -1.80	3.4	-152.94% (-5.20)	―	―
Aug 03, 2023	2023 (Q2)	-2.60 / -2.80	-3.8	26.32% (+1.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CDTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$19.15	$18.63	-2.72%
Mar 06, 2025	$23.61	$23.66	+0.21%
Nov 07, 2024	$13.11	$13.50	+2.97%
Aug 13, 2024	$12.15	$12.86	+5.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cidara Therapeutics Inc. (CDTX) report earnings?

Cidara Therapeutics Inc. (CDTX) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Cidara Therapeutics Inc. (CDTX) earnings time?

Cidara Therapeutics Inc. (CDTX) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CDTX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing